Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 2/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 3/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 3/20 | 0.31 |
| ▸ | LDHB | P07195 | 3/20 | 0.31 |
| ▸ | CDC42 | P60953 | 2/20 | 0.31 |
| ▸ | RAC1 | P63000 | 2/20 | 0.31 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192066 | 0.88 | BCL2 (0.41) | BCL2BCL2L1MCL1BCL2L2ALB | |
| SCHEMBL17192075 | 0.76 | GABRA1 (0.37) | BCL2BCL2L1MCL1MEN1USP2 | |
| SCHEMBL17191925 | 0.74 | ALOX15 (0.31) | KDM4EMEN1USP2ALDH1A1LMNA | |
| SCHEMBL19420687 | 0.73 | PTPN22 (0.42) | CDC42RAC1RNASEH1KDM4EMEN1 | |
| SCHEMBL17192073 | 0.73 | GABRA1 (0.37) | LMNACYP1A2CYP3A4HPGDBLM | |
| SCHEMBL20869600 | 0.73 | CDC42 (0.32) | CDC42RAC1 | |
| SCHEMBL17192065 | 0.73 | GABRA1 (0.37) | LMNACYP1A2CYP3A4HPGDBLM | |
| SCHEMBL19202196 | 0.73 | TRPM4 (0.50) | BCL2BCL2L1MCL1BCL2L2AHR | |
| SCHEMBL19420685 | 0.72 | ESR1 (0.31) | ESR1 | |
| SCHEMBL10714695 | 0.67 | MCL1 (0.49) | BCL2BCL2L1MCL1BCL2L2ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | BCL2 1976/4885BCL2L1 1180/4885MCL1 1591/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | BCL2 2021/4885BCL2L1 1207/4885MCL1 1079/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | BCL2 1976/4885BCL2L1 1180/4885MCL1 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.